Vivien Rothe

405 total citations
8 papers, 311 citations indexed

About

Vivien Rothe is a scholar working on Hepatology, Epidemiology and Oncology. According to data from OpenAlex, Vivien Rothe has authored 8 papers receiving a total of 311 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Hepatology, 5 papers in Epidemiology and 2 papers in Oncology. Recurrent topics in Vivien Rothe's work include Hepatitis B Virus Studies (5 papers), Hepatitis C virus research (5 papers) and Liver Disease Diagnosis and Treatment (5 papers). Vivien Rothe is often cited by papers focused on Hepatitis B Virus Studies (5 papers), Hepatitis C virus research (5 papers) and Liver Disease Diagnosis and Treatment (5 papers). Vivien Rothe collaborates with scholars based in France, Switzerland and Germany. Vivien Rothe's co-authors include Patrick Marcellin, Hans‐Peter Kapprell, M. Popescu, Maurizia Rossana Brunetto, Stephanos J. Hadziyannis, Ferruccio Bonino, Cihan Yurdaydın, Teerha Piratvisuth, Zhi‐Meng Lu and Rami Moucari and has published in prestigious journals such as Journal of Hepatology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

Vivien Rothe

8 papers receiving 302 citations

Peers

Countries citing papers authored by Vivien Rothe

Since Specialization

Citations

This map shows the geographic impact of Vivien Rothe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vivien Rothe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vivien Rothe more than expected).

Fields of papers citing papers by Vivien Rothe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vivien Rothe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vivien Rothe. The network helps show where Vivien Rothe may publish in the future.

Co-authorship network of co-authors of Vivien Rothe

This figure shows the co-authorship network connecting the top 25 collaborators of Vivien Rothe. A scholar is included among the top collaborators of Vivien Rothe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vivien Rothe. Vivien Rothe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

#	Title	Journal	Authors	Indexed citations
1	Noninferiority of cetuximab every-2-weeks versus standard once-weekly administration schedule for the first-line treatment of RAS wild-type metastatic colorectal cancer	European Journal of Cancer	Stefan Kasper, Diethelm Messinger et al.	7
2	Noninferiority on overall survival of every-2-weeks vs weekly schedule of cetuximab for first-line treatment of RAS wild-type metastatic colorectal cancer	Annals of Oncology	Stefan Kasper, Ann‐Lii Cheng et al.	3
3	A Genotype-Specific Baseline Score to Predict Response at 48 Weeks Post-Treatment to Peginterferon Alfa-2a in Patients with HBeAg-Negative Chronic Hepatitis B	Journal of Hepatology	Pietro Lampertico, Diethelm Messinger et al.	3
4	Serum Levels of Hepatitis B Surface Antigen Predict Severity of Fibrosis in Patients With E Antigen-Positive Chronic Hepatitis B	Clinical Gastroenterology and Hepatology	Patrick Marcellin, Michelle Martinot-Peignoux et al.	13
5	Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: On-treatment kinetics of HBsAg serum levels vary by HBV genotype	Journal of Hepatology	Maurizia Rossana Brunetto, Patrick Marcellin et al.	76
6	Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients	Hepatology International	Patrick Marcellin, Ferruccio Bonino et al.	120
7	524 RESPONSE-GUIDED PEGINTERFERON ALFA-2A THERAPY BASED ON HBSAG LEVELS AT WEEK 12 AND WEEK 24 OR 48 IMPROVES RESPONSE RATES IN HBEAG-NEGATIVE, GENOTYPE D PATIENTS	Journal of Hepatology	Pietro Lampertico, Mauro Viganò et al.	4
8	Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients	Hepatology International	Teerha Piratvisuth, Patrick Marcellin et al.	85

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact